Lumicitabine
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Lumicitabine
- Molecular weight
- 433.86
- Structure (SMILES)
- CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C
- als 008176
- als 8176
- ALS-008176
- ALS-008176 (250 mg)
- ALS-008176 (500 mg)
- ALS-008176 (750 mg)
- Als-8176
- Formulation A (ALS-008176)
- Formulation B (ALS-008176)
- Formulation C (ALS-008176)
- Formulation D (ALS-008176)
- Formulation E (ALS-008176)
- Formulation F (ALS-008176)
- Formulation G1 (ALS-008176)
- Formulation G2 (ALS-008176)
- Formulation G3 (ALS-008176)
- Formulation H1 (ALS-008176)
- Formulation H2 (ALS-008176)
- Formulation H3 (ALS-008176)
- lumicitabina
- Lumicitabina
- lumicitabine
- Lumicitabine
- lumicitabine [INN]
- LUMICITABINE [USAN]
And 4 more, listed on the interactive page.
- CAS registry numbers
- 1445385-02-3
- ChEMBL ID
- CHEMBL3417258
- InChIKey
- MJVKYGMNSQJLIN-KYZVSKTDSA-N
- PubChem compound IDs
- 89658382
- FDA ingredient codes (UNII)
- BNW5PQ52G1
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -citabine
Mechanisms of action
- Mechanism
- RNA-directed RNA polymerase L inhibitor
- Action type
- Inhibitor
- Target
- RNA-directed RNA polymerase L
- Protein identifier
- P28887
Open Targets mechanisms
- Mechanism
- RNA-directed RNA polymerase L inhibitor
- Action type
- Inhibitor
- Target
- RNA-directed RNA polymerase L
Investigated indications
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001475
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001577
- Highest recorded phase
- 2
- NCT01906164
- NCT02094365
- NCT02202356
- NCT02231671
- NCT02478333
- NCT02673476
- NCT02935673
- NCT03332459
- NCT03333317
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 1
- Polar surface area
- 122.74
- Calculated partition coefficient (ALogP)
- 1.44
- Calculated partition coefficient (XLogP)
- 1.5
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 29
- Molecular formula
- C18H25ClFN3O6
- Monoisotopic mass
- 433.1415914
- Natural product
- No
- Recorded assays
- 25
- Active assays
- 6
Active assay types
- Confirmatory
Oral bioavailability
- Median
- 43.5
- Mean
- 59.6333
- Minimum
- 38.2
- Maximum
- 97.2
- Unit
- %
- Assays
- 3
- Standard deviation
- 32.6414
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (80)
- A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
- A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
- A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
- A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
- A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
- A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
- A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
- A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
- A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
- A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
- A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
- A Study of ALS-008176 in Infants Hospitalized With RSV
- A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
- A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants
- A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers
- A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
- A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
- A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants